Infection with SARS-CoV-2 can cause pancreatic impairment
© 2024. The Author(s)..
Evidence suggests associations between COVID-19 patients or vaccines and glycometabolic dysfunction and an even higher risk of the occurrence of diabetes. Herein, we retrospectively analyzed pancreatic lesions in autopsy tissues from 67 SARS-CoV-2 infected non-human primates (NHPs) models and 121 vaccinated and infected NHPs from 2020 to 2023 and COVID-19 patients. Multi-label immunofluorescence revealed direct infection of both exocrine and endocrine pancreatic cells by the virus in NHPs and humans. Minor and limited phenotypic and histopathological changes were observed in adult models. Systemic proteomics and metabolomics results indicated metabolic disorders, mainly enriched in insulin resistance pathways, in infected adult NHPs, along with elevated fasting C-peptide and C-peptide/glucose ratio levels. Furthermore, in elder COVID-19 NHPs, SARS-CoV-2 infection causes loss of beta (β) cells and lower expressed-insulin in situ characterized by islet amyloidosis and necrosis, activation of α-SMA and aggravated fibrosis consisting of lower collagen in serum, an increase of pancreatic inflammation and stress markers, ICAM-1 and G3BP1, along with more severe glycometabolic dysfunction. In contrast, vaccination maintained glucose homeostasis by activating insulin receptor α and insulin receptor β. Overall, the cumulative risk of diabetes post-COVID-19 is closely tied to age, suggesting more attention should be paid to blood sugar management in elderly COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Signal transduction and targeted therapy - 9(2024), 1 vom: 12. Apr., Seite 98 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deng, Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 25.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41392-024-01796-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370986776 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370986776 | ||
| 003 | DE-627 | ||
| 005 | 20240425234118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41392-024-01796-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370986776 | ||
| 035 | |a (NLM)38609366 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deng, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Infection with SARS-CoV-2 can cause pancreatic impairment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Evidence suggests associations between COVID-19 patients or vaccines and glycometabolic dysfunction and an even higher risk of the occurrence of diabetes. Herein, we retrospectively analyzed pancreatic lesions in autopsy tissues from 67 SARS-CoV-2 infected non-human primates (NHPs) models and 121 vaccinated and infected NHPs from 2020 to 2023 and COVID-19 patients. Multi-label immunofluorescence revealed direct infection of both exocrine and endocrine pancreatic cells by the virus in NHPs and humans. Minor and limited phenotypic and histopathological changes were observed in adult models. Systemic proteomics and metabolomics results indicated metabolic disorders, mainly enriched in insulin resistance pathways, in infected adult NHPs, along with elevated fasting C-peptide and C-peptide/glucose ratio levels. Furthermore, in elder COVID-19 NHPs, SARS-CoV-2 infection causes loss of beta (β) cells and lower expressed-insulin in situ characterized by islet amyloidosis and necrosis, activation of α-SMA and aggravated fibrosis consisting of lower collagen in serum, an increase of pancreatic inflammation and stress markers, ICAM-1 and G3BP1, along with more severe glycometabolic dysfunction. In contrast, vaccination maintained glucose homeostasis by activating insulin receptor α and insulin receptor β. Overall, the cumulative risk of diabetes post-COVID-19 is closely tied to age, suggesting more attention should be paid to blood sugar management in elderly COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Receptor, Insulin |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a C-Peptide |2 NLM | |
| 650 | 7 | |a DNA Helicases |2 NLM | |
| 650 | 7 | |a EC 3.6.4.- |2 NLM | |
| 650 | 7 | |a Poly-ADP-Ribose Binding Proteins |2 NLM | |
| 650 | 7 | |a RNA Helicases |2 NLM | |
| 650 | 7 | |a EC 3.6.4.13 |2 NLM | |
| 650 | 7 | |a RNA Recognition Motif Proteins |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a G3BP1 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.6.4.12 |2 NLM | |
| 700 | 1 | |a Bao, Linlin |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Zhiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yanfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Wenjie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiuqin |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Yunlin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yanhong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jiangning |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Xujian |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Fengdi |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Feifei |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Siyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Yibai |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Ruiping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hongyang |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Chuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Signal transduction and targeted therapy |d 2016 |g 9(2024), 1 vom: 12. Apr., Seite 98 |w (DE-627)NLM257871861 |x 2059-3635 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:1 |g day:12 |g month:04 |g pages:98 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41392-024-01796-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 1 |b 12 |c 04 |h 98 | ||